Company News
Crinetics Reports Phase‑2 CAH Data, Revenue Beats
Crinetics presented Phase 2 results for atumelnant in CAH, showing 67% mean reduction in androstenedione at 80 mg dose after 12 weeks.
The trial also reported 64% and 56% mean decreases in 11‑OHA4 and
